首站-论文投稿智能助手
典型文献
Identification and characterization of blocking nanobodies against human CD70
文献摘要:
CD70 is overexpressed in a variety of solid and hematological tumors and plays a role in tumor proliferation and evasion of immune surveillance.Targeting and blocking its binding to the receptor CD27 have the potential to treat CD70-dependent tumors.To generate novel CD70 blocking agents,we screen a human CD70-immunized camel VHH phage display library and isolate two blocking nanobodies against human CD70 targeting different epitopes.Upon enrichment by three rounds of biopanning,two strategies are employed to identify CD70 blockers.One named affinity selection is used for detecting clones with CD70 binding by conventional PE-ELISA.However,no clone with a blocking effect is obtained from 188 enriched clones by this method.The alternative strategy named competitive selection is based on the inhibiting capacity of CD70-CD27 binding by enriched VHHs.By this method,two clones,Nb-2B3 and Nb-3B6,with strong blocking capacity are obtained from 20 enriched VHHs,suggesting the efficiency of this strategy.Furthermore,Nb-2B3 and Nb-3B6 specifically bind to CD70-positive SKOV3 and Raji cells at low concentrations.Meanwhile,Nb-2B3 has no competitive effect on the binding of Nb-3B6 to CD70,and vice versa,indicating that they target two different epitopes on CD70.Our data show that nanobodies Nb-2B3 and Nb-3B6 are potential attractive theranostic agents for CD70-expressing cancers.
文献关键词:
作者姓名:
Xin Zhang;Chang Liu;Yuan Xie;Qianqian Hu;Yuanyuan Chen;Jiangwei Li
作者机构:
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering,College of Life Science and Technology,Xinjiang University,Urumqi 830046,China;Xinjiang Unique Mab BioTech Co.,Ltd,Urumqi 830002,China
引用格式:
[1]Xin Zhang;Chang Liu;Yuan Xie;Qianqian Hu;Yuanyuan Chen;Jiangwei Li-.Identification and characterization of blocking nanobodies against human CD70)[J].生物化学与生物物理学报(英文版),2022(10):1518-1527
A类:
biopanning,VHHs,2B3,3B6
B类:
Identification,characterization,blocking,nanobodies,against,human,CD70,overexpressed,variety,solid,hematological,tumors,plays,role,proliferation,evasion,immune,surveillance,Targeting,its,binding,receptor,CD27,have,potential,treat,dependent,To,generate,novel,agents,screen,immunized,camel,phage,display,library,isolate,two,targeting,different,epitopes,Upon,enrichment,by,three,rounds,strategies,are,employed,identify,blockers,One,named,affinity,selection,used,detecting,clones,conventional,PE,However,effect,obtained,from,enriched,this,method,alternative,strategy,competitive,inhibiting,capacity,By,Nb,strong,suggesting,efficiency,Furthermore,specifically,positive,SKOV3,Raji,cells,low,concentrations,Meanwhile,has,vice,versa,indicating,that,they,Our,data,show,attractive,theranostic,expressing,cancers
AB值:
0.454747
相似文献
Potential medicinal plants involved in inhibiting 3CLpro activity:A practical alternate approach to combating COVID-19
Fan Yang;Xiao-lan Jiang;Akash Tariq;Sehrish Sadia;Zeeshan Ahmed;Jordi Sardans;Muhammad Aleem;Riaz Ullah;Rainer W.Bussmann-The Medical Center of General Practice,Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital,Chengdu 610041,Sichuan Province,China;Xinjiang Institute of Ecology and Geography,Chinese Academy of Sciences,Urumqi 830041,Xinjiang Uygur Autonomous Region,China;Department of Biological Sciences,University of Veterinary and Animal Sciences,Ravi Campus,Pattoki 55300,Pakistan;Consejo Superior de Investigaciones Científicas,Global Ecology Unit,Centre for Ecological Research and Forestry Applications-Consejo Superior de Investigaciones Cientificas-Universitat Autònoma de Barcelona,Bellaterra,Barcelona 08193,Catalonia,Spain;Centre for Ecological Research and Forestry Applications,Cerdanyola del Vallès 08193,Catalonia,Spain;Department of Pharmacognosy,College of Pharmacy,King Saud University,Riyadh 11451,Saudi Arabia;Department of Ethnobotany,Institute of Botany,Ilia State University,Tbilisi 0105,Georgia
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Yi Xiao;Ding Ma;Yun-Song Yang;Fan Yang;Jia-Han Ding;Yue Gong;Lin Jiang;Li-Ping Ge;Song-Yang Wu;Qiang Yu;Qing Zhang;Francois Bertucci;Qiuzhuang Sun;Xin Hu;Da-Qiang Li;Zhi-Ming Shao;Yi-Zhou Jiang-Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,China;Human Phenome Institute,Fudan University,Shanghai,China;Department of Pathology,University of Texas Southwestern Medical Center,Dallas,TX,USA;Predictive Oncology team,Centre de Recherche en Cancérologie de Marseille(CRCM),INSERM UMR1068,CNRS UMR725,Aix-Marseille Université,Institut Paoli-Calmettes,Marseille,France;Department of Industrial Systems Engineering and Management,National University of Singapore,Singapore,Singapore
Structures of the endogenous peptide-and selective non-peptide agonist-bound SSTR2 signaling complexes
Li-Nan Chen;Wei-Wei Wang;Ying-Jun Dong;Dan-Dan Shen;Jia Guo;Xuefei Yu;Jiao Qin;Su-Yu Ji;Huibing Zhang;Qingya Shen;Qiaojun He;Bo Yang;Yan Zhang;Qinglin Li;Chunyou Mao-Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital,Zhejiang University,School of Medicine,Hangzhou,Zhejiang,China;Department of General Surgery,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Center for Structural Pharmacology and Therapeutics Development,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang,China;The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China;Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou,Zhejiang,China;MOE Frontier Science Center for Brain Research and Brain-Machine Integration,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Zhejiang Provincial Key Laboratory of Immunity and Inflammatory diseases,Hangzhou,Zhejiang,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays
Jin-ping Pang;Chao Shen;Wen-fang Zhou;Yun-xia Wang;Lu-hu Shan;Xin Chai;Ying Shao;Xue-ping Hu;Feng Zhu;Dan-yan Zhu;Li Xiao;Lei Xu;Xiao-hong Xu;Dan Li;Ting-jun Hou-Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences,Cancer Hospital of University of Chinese Academy of Sciences,Zhejiang Cancer Hospital,Hangzhou 310022,China;School of Life Science,Huzhou University,Huzhou 313000,China;Institute of Bioinformatics and Medical Engineering,School of Electrical and Information Engineering,Jiangsu University of Technology,Changzhou 213001,China;State Key Lab of CAD&CG,Zhejiang University,Hangzhou 310058,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。